Case Details
- Citation: [2018] SGHC 178
- Title: China Medical Technologies, Inc (in liquidation) and another v Wu Xiaodong and another
- Court: High Court of the Republic of Singapore
- Date of Decision: 13 August 2018
- Judge: Audrey Lim JC
- Case Number: Suit No 1180 of 2017 (Summonses Nos 5689 of 2017 and 878 of 2018)
- Procedural Context: Application for Mareva injunction (SUM 5689); application to stay proceedings (SUM 878)
- Plaintiffs/Applicants: China Medical Technologies, Inc (in liquidation) (“P1”) and another (“P2”)
- Defendants/Respondents: Wu Xiaodong (“Wu”) and Bi Xiaoqiong (“Bi”)
- Parties (additional description): Bi was sued in her personal capacity and as trustee of the Xiao Qiong Bi Trust and the Alisa Wu Irrevocable Trust
- Legal Area: Civil Procedure — Injunctions (Mareva injunctions)
- Key Issues: (i) Whether Singapore courts have power to grant a Mareva injunction in aid of foreign court proceedings; (ii) whether there is a good arguable case; (iii) whether there is a real risk of asset dissipation
- Counsel for Plaintiffs: Kelvin Poon / Nigel Pereira / Chew Xiang / Quek Teck Liang (Rajah & Tann Singapore LLP)
- Counsel for Second Defendants: Hee Teng Fong / Tan Chau Yee / Sharmini Selvaratnam / Andrea Koh (Eversheds Harry Elias LLP)
- Judgment Length: 23 pages, 13,954 words
- Appeal Note: The appeal in Civil Appeal No 188 of 2018 was dismissed by the Court of Appeal on 30 April 2019 (see [2019] SGCA 50)
- Statutes Referenced (as per metadata): British Columbia Law and Equity Act; British Columbia Law and Equity Act 1979; Civil Jurisdiction and Judgments Act; Civil Jurisdiction and Judgments Act 1982; Civil Law Act; Federal Courts Act; Federal Courts Act 1985; High Court Ordinance (Cap 4)
Summary
China Medical Technologies, Inc (in liquidation) and another v Wu Xiaodong and another [2018] SGHC 178 is a High Court decision addressing the scope of Singapore’s power to grant Mareva injunctions in support of foreign proceedings. The case arose from allegations that the plaintiffs’ former management orchestrated a large-scale fraud involving the purchase of medical technologies, with funds allegedly routed through entities associated with the defendants. Parallel proceedings were commenced in Hong Kong, and the plaintiffs sought interim asset-freezing relief in Singapore to prevent dissipation of assets located in Singapore.
The central legal question was whether the Singapore court has power under s 4(10) of the Civil Law Act (Cap 43) to grant a Mareva injunction “in aid of” foreign court proceedings, particularly where the Singapore court has in personam jurisdiction over the defendant. The court also had to assess whether the plaintiffs established the usual Mareva requirements, including a good arguable case and a real risk of asset dissipation. The judge’s analysis clarified the relationship between Singapore’s statutory power to grant injunctions and the principles governing Mareva relief connected to foreign litigation.
What Were the Facts of This Case?
The first plaintiff, China Medical Technologies, Inc (“P1”), is a public company incorporated in the Cayman Islands. The second plaintiff, P2, is a wholly-owned subsidiary of P1. Around February 2007 and October 2008, P1 and P2 acquired medical technologies for approximately US$521.8m from Supreme Well Investments Limited (“SW”) and SW’s subsidiary. P1 was subsequently wound up in July 2012, and liquidators investigated the company’s affairs.
Following the winding up, the liquidators alleged that the technologies purchased were substantially worthless and that SW was a sham entity controlled by P1’s former management, including the first defendant, Wu Xiaodong, and another former director and chief financial officer, Tsang. The plaintiffs’ case was that they were victims of fraudulent misappropriation of the US$521.8m, and that Wu and other directors orchestrated and participated in the fraud (referred to in the judgment as “the Fraud”). The plaintiffs alleged that funds transferred from P1 and P2 to SW were distributed to bank accounts of “SW Payees” apparently associated with or controlled by Wu and Tsang and/or their associates, and that those funds were then transferred onward to “Further SW Payees”, including Wu and the second defendant, Bi.
Bi married Wu in 1995 and entered into a divorce agreement in 2012, though Bi claimed that she and Wu had been separated since 2001. This relationship featured in the plaintiffs’ narrative of how assets were held and moved, and it became relevant to the plaintiffs’ attempt to freeze assets in Singapore that were alleged to be connected to the Fraud or to the defendants’ control.
In terms of litigation, P1 commenced an action in the Hong Kong High Court on 1 August 2013 (“the first HK suit”) against Wu and four others, seeking relief including breach of fiduciary duties, breach of trust, fraud, conspiracy, knowing receipt, dishonest assistance, and money had and received. On 23 December 2016, P1 and P2 commenced a second Hong Kong action (“the second HK suit”) against Wu, Bi, and 21 others, adding further claims. The plaintiffs intended to consolidate the first and second HK suits later. The writ in the second HK suit was served on Bi’s solicitors on 27 November 2017.
On 11 December 2017, the Hong Kong court granted P1 and P2 a worldwide Mareva injunction against Wu and Bi in the second HK suit (“the HK injunction”), covering assets in Singapore. Shortly thereafter, on 13 December 2017, P1 and P2 filed a writ in Singapore for substantially the same causes of action and relief as in the second HK suit (“Suit 1180”). Concurrently, they applied for a Mareva injunction against Wu and Bi in Singapore (SUM 5689) to prevent disposal of Singapore assets already covered by the HK injunction. Bi was served with the Singapore writ, SUM 5689 papers, and the HK injunction order on 18 December 2017. On 4 January 2018, the Singapore court granted a Mareva injunction ex parte against Wu in SUM 5689. Before Audrey Lim JC, SUM 5689 remained to be determined against Bi, while the plaintiffs also applied to stay Suit 1180 (SUM 878) in favour of Hong Kong as the more appropriate forum, pending the final determination of the Hong Kong suits.
What Were the Key Legal Issues?
The first and most significant issue was whether Singapore courts have the power to grant a Mareva injunction in aid of foreign court proceedings. The plaintiffs’ primary purpose in commencing Suit 1180 and applying for SUM 5689 was to obtain interim asset-freezing relief in Singapore to support the Hong Kong proceedings. Bi’s position was that the Singapore court lacked such power, and that even if power existed, the injunction should not be granted on the facts.
Closely connected to the first issue was the statutory interpretation question concerning s 4(10) of the Civil Law Act. The court had to consider whether s 4(10) confers a power to grant interim relief in aid of foreign proceedings, especially where the Singapore court has in personam jurisdiction over the defendant and the plaintiff has a reasonable accrued cause of action recognisable in Singapore. The judgment also addressed the conceptual distinction between “jurisdiction” and “power” in this context, emphasising that the court’s authority to hear and determine the dispute is an anterior question to the exercise of any injunctive power.
In addition to the power issue, the court had to determine whether the plaintiffs satisfied the substantive requirements for Mareva relief against Bi. These included whether there was a good arguable case and whether there was a real risk that Bi would dissipate assets in Singapore to frustrate the plaintiffs’ claims. The court also had to consider the effect of the existing HK injunction and the procedural posture of the Singapore action, including the plaintiffs’ intention to stay the Singapore proceedings pending the Hong Kong outcome.
How Did the Court Analyse the Issues?
Audrey Lim JC began by framing the dispute as one about the court’s “power” rather than its “jurisdiction”. While some authorities had used the terms interchangeably, the judge explained that “jurisdiction” in this setting refers to the court’s authority to hear and determine a dispute brought before it, whereas s 4(10) of the Civil Law Act confers a power to grant injunctions. This distinction mattered because the court must first have proper in personam jurisdiction over the defendant and a justiciable cause of action before it can consider whether it should exercise its injunctive power.
The judge then addressed the state of the law. She noted a divergence of views in the High Court regarding the ambit of s 4(10). In Petroval SA v Stainby Overseas Ltd and others [2008] 3 SLR(R) 856 (“Petroval”), the court held that it had no jurisdiction to grant a Mareva injunction in aid of foreign court proceedings. In that case, the Singapore action was commenced solely to obtain interim relief, with the merits to be determined elsewhere (in the BVI). The court set aside the interlocutory relief and the Singapore proceedings because the substantive claim was not intended to be determined in Singapore.
By contrast, in Multi-Code Electronics Industries (M) Bhd and another v Toh Chun Toh Gordon and others [2009] 1 SLR(R) 1000 (“Multi-Code”), the court upheld a Mareva injunction in circumstances where the Singapore action was duplicitous with a Malaysian action. Chan Seng Onn J treated s 4(10) as providing a residual jurisdiction over the underlying cause of action that could ground the court’s ability to grant or allow the continuation of a domestic Mareva injunction against assets in Singapore even if the Singapore action was stayed. However, Chan J identified prerequisites: the Singapore court must have in personam jurisdiction; and the stayed action must not be struck out or set aside for lack of jurisdiction or absence of a reasonable accrued cause of action.
Both Petroval and Multi-Code had relied on Swift-Fortune Ltd v Magnifica Marine SA [2007] 1 SLR(R) 629 (“Swift-Fortune”), which concerned Mareva injunctions in aid of foreign arbitrations. In Swift-Fortune, the Court of Appeal held that the then statutory provision in the International Arbitration Act did not apply to foreign arbitrations, and that the court’s power had to be found in other statutory sources, including s 4(10) of the Civil Law Act read with the relevant provisions of the Supreme Court of Judicature Act. The Court of Appeal concluded that s 4(10) did not confer power to grant a Mareva injunction against assets in Singapore unless the plaintiff had an accrued cause of action justiciable in Singapore.
Against this background, the judge in China Medical Technologies had to decide whether the reasoning in Swift-Fortune and the divergent High Court approaches in Petroval and Multi-Code should be applied to foreign court proceedings. The judgment emphasised that the plaintiffs in the present case did have a reasonable accrued cause of action recognisable in Singapore, and that the Singapore court had in personam jurisdiction over Bi. Bi, as a Singapore citizen, had been properly served with the Singapore writ. It was therefore not a case where the Singapore action was merely a vehicle to obtain interim relief without any real justiciable claim in Singapore.
In analysing the Mareva requirements, the court considered whether the plaintiffs had established a “good arguable case” on the merits. The allegations of fraud, the alleged sham nature of SW, and the alleged routing of funds through SW Payees and Further SW Payees associated with Wu and Bi were treated as sufficient to clear the threshold for arguability at the interlocutory stage. The court also considered the risk of dissipation. The plaintiffs’ evidence and narrative pointed to a pattern of transfers and onward movement of funds, which supported the inference that assets could be moved away from Singapore to frustrate enforcement.
Finally, the court considered the practical and doctrinal significance of the existing HK injunction. While the HK injunction already covered assets in Singapore, the Singapore Mareva application served to ensure enforceability and effectiveness within Singapore’s jurisdiction. The court’s approach reflected a balancing exercise: it recognised the importance of comity and the appropriateness of Hong Kong as the forum for determining the substantive dispute, while still acknowledging that interim relief may be necessary to preserve assets pending the foreign court’s final determination.
What Was the Outcome?
The High Court decided that the Singapore court had the power to grant a Mareva injunction in aid of foreign court proceedings, provided the prerequisites were satisfied—most importantly, that the Singapore court had in personam jurisdiction over the defendant and that the plaintiffs had a reasonable accrued cause of action justiciable in Singapore. Applying those principles, the court granted the Mareva injunction against Bi (with the injunction remaining subject to the usual conditions and procedural safeguards associated with Mareva relief).
In parallel, the court addressed the plaintiffs’ application to stay Suit 1180 pending the determination of the Hong Kong proceedings. The practical effect of the decision was that the substantive dispute would proceed in Hong Kong, but the Singapore Mareva injunction would operate to preserve assets in Singapore so that any eventual judgment could be made effective.
Why Does This Case Matter?
China Medical Technologies is significant because it provides authoritative guidance on the scope of Singapore’s Mareva jurisdiction in support of foreign litigation. For practitioners, the decision clarifies that s 4(10) of the Civil Law Act can be engaged to grant interim asset-freezing relief connected to foreign court proceedings, rather than being limited to purely domestic disputes. This is particularly relevant in cross-border fraud and asset-tracing cases where defendants hold assets in Singapore but the substantive claims are pursued abroad.
The case also matters for its doctrinal clarification of the “power” versus “jurisdiction” distinction. By emphasising that the court must first have proper in personam jurisdiction and a justiciable accrued cause of action, the judgment provides a structured framework for assessing whether Mareva relief can be granted without undermining the integrity of Singapore’s adjudicative role. This framework helps litigators anticipate objections that Singapore is being used merely as an enforcement or interim-relief forum.
Finally, the decision has practical implications for how plaintiffs structure proceedings where a foreign court has already granted a worldwide Mareva injunction. The court’s willingness to grant Singapore relief, even where a stay is contemplated, supports the view that interim measures can be necessary to preserve assets and ensure meaningful enforcement. The subsequent dismissal of the appeal by the Court of Appeal (see [2019] SGCA 50) further strengthens the precedential value of the High Court’s approach.
Legislation Referenced
- Civil Law Act (Cap 43)
- High Court Ordinance (Cap 4)
- Civil Jurisdiction and Judgments Act
- Civil Jurisdiction and Judgments Act 1982
- Federal Courts Act
- Federal Courts Act 1985
- British Columbia Law and Equity Act
- British Columbia Law and Equity Act 1979
Cases Cited
- Petroval SA v Stainby Overseas Ltd and others [2008] 3 SLR(R) 856
- Multi-Code Electronics Industries (M) Bhd and another v Toh Chun Toh Gordon and others [2009] 1 SLR(R) 1000
- Swift-Fortune Ltd v Magnifica Marine SA [2007] 1 SLR(R) 629
- Re Nalpon Zero Geraldo Mario [2013] 3 SLR 258
- China Medical Technologies, Inc (in liquidation) and another v Wu Xiaodong and another [2018] SGHC 178
- Civil Appeal No 188 of 2018 (dismissed) — see [2019] SGCA 50
Source Documents
This article analyses [2018] SGHC 178 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.